Explore the Science Behind Simple Ultrasensitive Biomarker Quantitation

Our SPLASH™ (Solid Phase Ligation Assay with Single wasH) technology pairs an antibody probe with a single wash step and standard qPCR to deliver ultrasensitive, specific, and accurate results without specialized instrumentation.

SPLASH maximizes signal while minimizing background

Digital immunoassays and no-wash chemistries have driven real advances in neurodegenerative disease blood-based biomarker quantitation, but they often come with reagent complexity, run-to-run variability, and performance drift over time. SPLASH™ takes a different approach: by combining qPCR-based signal amplification with antibody-based targeting and a bead-based wash step, it maximizes signal while physically washing away background interference, delivering the sensitivity of specialized ultrasensitive platforms without requiring one.

Download the white paper to learn how our single-wash SPLASH platform transform Alzheimer’s diagnosis and accelerate therapeutic development

SPLASH is a highly specific, ultrasensitive, and scalable assay for protein biomarker quantification

icn-antibody

Specific

While conventional PLA utilizes oligo-conjugated antibodies, our SPLASH technology incorporates an additional binding moiety onto one antibody in the probe pair. This enables selective capture of the formed immunocomplex.

icn-antibody-unbound

Ultrasensitive

Unbound probes and interfering substances are washed away, while the immunocomplex is captured and quantified.

icn-simple-workflow

Scalable and Simple

Our highly scalable workflow can be fully automated or performed manually, requiring no additional instruments.

See how SPLASH technology works

See our 2026 AD/PD posters

Development of an ultrasensitive, scalable Solid Phase Ligation Assay with Single wasH (SPLASH) based immunoassay for the quantitation of LRRK2

Presented at AD/PD 2026

Multi-platform Quantitation Of Alzheimer’s Disease Biomarkers Using A Multiplex Assay Compatible With qPCR and dPCR

Presented at AD/PD 2026

Simultaneous Quantitation of pTau-217, Aβ42, NfL, and GFAP in Plasma Using a Novel Multiplex Assay for Alzheimer’s Disease Staging and Monitoring

Presented at AD/PD 2026

FAQ

How is SPLASH™ different from a standard proximity ligation assay (PLA)?

Conventional PLA relies on oligo-conjugated antibodies alone. SPLASH™ adds a second binding moiety, biotin, onto one antibody in the probe pair. This lets the immunocomplex be physically captured on streptavidin-coated magnetic beads before quantification, rather than relying on ligation chemistry alone to generate signal. The result is more selective capture of the target and a cleaner separation from background before the sample ever reaches the qPCR instrument.

Digital immunoassays and no-wash chemistries have driven real advances in ultrasensitive detection, but they can be prone to reagent complexity, run-to-run variability, and performance drift over time. SPLASH™ physically washes away unbound antibodies and interfering substances from the sample matrix before quantification, rather than managing interference through reagent design alone. This is also why SPLASH™ can report consistent results across studies and sites, since the same physical wash step is applied every run, regardless of instrument or operator.

Feature Taudia SPLASH Simoa MSD ELISA
Uses existing qPCR
Ultrasensitive ~ ~
Multiplex capability (5+) Limited (10+) Limited
Specialized instrument No Yes Yes No
Workflow complexity Low Moderate Moderate Moderate
Cost per sample Low High Moderate Low

Both. SPLASH™ can be run as a fully manual benchtop workflow, or scaled through NeuXplore™, Taudia’s automated sample-to-answer platform. On the automated system, a typical run processes up to 48 samples in under 4 hours. The same three-step chemistry (incubate, wash, quantify) underlies both formats, so results are designed to be comparable whether a lab is running manually or at scale.

  • SPLASH™ has demonstrated quantification of pTau-217 down to femtogram-per-milliliter concentrations, made possible by physically washing away background interference before quantification.
  • The platform has clearly differentiated AD-positive from AD-negative patient samples in independent testing, with excellent spike-and-recovery performance, ensuring measurements stay accurate and reliable even in complex biological matrices.
  • See our resource section to learn more.

Manual bench-top workflow: roughly 1–2 hours to incubate, 5–10 minutes to wash and capture, and about 1 hour for qPCR read-out, for a total of around 2–3 hours with less than 30 minutes of hands-on time. Automated (NeuXplore™) workflow: about 15 minutes to set up a run, followed by 3–4 hours of unattended automated processing.

Ready to get started?

Talk to our team so we can help you find the right kit, walk through the data, or scope a custom assay.